| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Biology and Medicine, Brown University, Providence, Rhode Island 02912
The uridine phosphorylase inhibitors, 5-benzylacyclouridine (BAU) and 5-benzyloxybenzylacyclouridine (BBAU) (Biochem. Pharmacol., 31: 1857, 1982), inhibited uptake of uridine in L5178Y cells. By a rapid sampling technique, BAU and BBAU were shown to inhibit the transport (zero-trans influx) of uridine, thymidine, and adenosine in human erythrocytes as well as in murine L5178Y cells. In all cases, competitive inhibitions were observed. Km values for the transport of adenosine, uridine, and thymidine in erythrocytes were 2.2, 195, and 199 µM, while Vmax were 2.9, 118, and 96.5 pmol/min/106 cells, respectively. In L5178Y cells, Km values of 14.8 and 23.1 µM and Vmax of 389 and 176 pmol/min/106 cells were obtained for adenosine and uridine, respectively. For erythrocytes, the Ki values of BAU were 127, 124, and 198 µM using adenosine, uridine, and thymidine as the substrate; and those of BBAU, 14.1 and 19.2 µM for adenosine and uridine, respectively. In L5178Y, the Ki values of BAU were 202 and 234 µM, and those of BBAU, 39.8 and 27.9 µM for adenosine and uridine, respectively. These data indicate that, in two cell types, Ki values for BAU and BBAU did not vary regardless of the substrate used; that the values of Ki are different for the erythrocytes and L5178Y cells; and that BBAU is at least 5-fold more potent than BAU as an inhibitor of nucleoside transport. The inhibitory effects on the efflux of preloaded uridine indicate that BAU and BBAU are inhibitors, rather than permeants, of the nucleoside transport system.
1 Supported by Grant CH-136 awarded by the American Cancer Society and by Grants CA-13943 and CA-31650 awarded by the National Cancer Institute, Department of Health and Human Services.
2 Recipient of support from the training program in cancer research, USPHS Grant CA 09204, awarded by the National Cancer Institute, Department of Health and Human Services.
3 To whom requests for reprints should be addressed.
Received 8/30/83. Accepted 5/23/84.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |